Steven Le Gouill Selected Research

Leukemia

1/2019	FLT3 ligand plasma levels have no impact on outcomes after allotransplant in acute leukemia.
11/2004	VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Steven Le Gouill Research Topics

Disease

28	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2022 - 08/2010
21	Lymphoma (Lymphomas) 01/2022 - 03/2002
19	Neoplasms (Cancer) 01/2022 - 09/2005
17	Multiple Myeloma 01/2021 - 11/2004
14	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2022 - 01/2009
11	Non-Hodgkin Lymphoma (Lymphosarcoma) 10/2022 - 03/2002
11	B-Cell Lymphoma (Lymphoma, B Cell) 10/2022 - 04/2011
10	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2022 - 07/2013
8	Disease Progression 01/2022 - 10/2007
6	Neutropenia 01/2022 - 06/2016
5	Hematologic Neoplasms (Hematological Malignancy) 10/2021 - 12/2009
5	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2021 - 01/2009
4	Infections 01/2022 - 01/2017
4	Graft vs Host Disease (Graft-Versus-Host Disease) 04/2021 - 01/2010
4	Residual Neoplasm 01/2021 - 01/2019
3	Waldenstrom Macroglobulinemia (Macroglobulinemia) 01/2022 - 06/2010
3	Lymphopenia (Lymphocytopenia) 01/2022 - 01/2020
3	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 10/2021 - 01/2019
3	Hodgkin Disease (Hodgkin's Disease) 01/2019 - 11/2009
3	Genetic Translocation (Chromosomal Translocation) 04/2015 - 09/2010
2	T-Cell Lymphoma (Lymphoma, T Cell) 01/2022 - 01/2013
2	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2021 - 04/2018
2	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2020 - 01/2017
2	Leukemia 01/2019 - 11/2004
2	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 03/2016 - 01/2013
2	Lymphocytosis 04/2015 - 08/2010
1	Macrophage Activation Syndrome 10/2022
1	Agammaglobulinemia (Hypogammaglobulinemia) 01/2022
1	Enterocolitis 01/2022
1	Fever (Fevers) 01/2022
1	Fever of Unknown Origin 01/2022
1	Septic Shock (Toxic Shock Syndrome) 01/2022
1	Stomatitis 01/2022

Drug/Important Bio-Agent (IBA)

25	Rituximab (Mabthera)FDA Link 01/2022 - 02/2010
10	Lenalidomide (CC 5013)FDA Link 01/2022 - 12/2004
8	obinutuzumabIBA 01/2022 - 10/2018
7	Bendamustine Hydrochloride FDA Link 01/2022 - 01/2013
6	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2022 - 06/2017
5	Cyclophosphamide (Cytoxan)FDA LinkGeneric 04/2021 - 07/2013
5	Melphalan (Alkeran)FDA LinkGeneric 01/2021 - 12/2005
5	venetoclaxIBA 01/2021 - 04/2015
5	Dexamethasone (Maxidex)FDA LinkGeneric 11/2020 - 07/2012
4	Biological ProductsIBA 01/2022 - 04/2015
4	Agammaglobulinaemia Tyrosine KinaseIBA 01/2022 - 04/2015
4	Etoposide (VP 16)FDA LinkGeneric 01/2021 - 04/2011
3	Chimeric Antigen ReceptorsIBA 10/2022 - 11/2020
3	tisagenlecleucelIBA 01/2022 - 11/2020
3	ibrutinibIBA 01/2022 - 04/2015
3	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2022 - 11/2020
3	CytokinesIBA 01/2021 - 09/2005
3	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 06/2017
3	Carboplatin (JM8)FDA LinkGeneric 01/2021 - 06/2017
3	Monoclonal AntibodiesIBA 06/2019 - 01/2016
3	Pharmaceutical PreparationsIBA 01/2018 - 09/2014
3	Cyclin D1IBA 04/2015 - 09/2010
2	Biomarkers (Surrogate Marker)IBA 01/2022 - 10/2020
2	axicabtagene ciloleucelIBA 07/2021 - 11/2020
2	Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA 01/2020 - 11/2011
2	Busulfan (Busulfex)FDA Link 01/2020 - 11/2011
2	purineIBA 01/2020 - 01/2016
2	acalabrutinibIBA 11/2019 - 01/2018
2	Proteasome InhibitorsIBA 06/2019 - 06/2019
2	flt3 ligand protein (flt3 ligand)IBA 01/2019 - 01/2019
2	Clofarabine (Clolar)FDA Link 01/2019 - 09/2018
2	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2019 - 11/2009
2	Proteins (Proteins, Gene)FDA Link 12/2018 - 06/2015
2	Janus Kinase InhibitorsIBA 07/2017 - 01/2009
2	fludarabineIBA 01/2016 - 11/2011
2	ibritumomab tiuxetan (Zevalin)FDA Link 01/2014 - 04/2011
2	Doxorubicin (Adriamycin)FDA LinkGeneric 07/2013 - 01/2009
2	InterferonsIBA 07/2013 - 08/2011
2	ABT-737IBA 10/2011 - 01/2011
2	Interleukin-6 (Interleukin 6)IBA 09/2005 - 11/2004
2	CaspasesIBA 09/2005 - 09/2005
1	NivolumabIBA 01/2022
1	atezolizumabIBA 01/2022
1	Gemcitabine FDA Link 01/2022
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2022
1	GlobulinsIBA 01/2022
1	Biological FactorsIBA 01/2021
1	pirtobrutinibIBA 01/2021
1	OligonucleotidesIBA 01/2021
1	KIR ReceptorsIBA 01/2021
1	LigandsIBA 01/2021
1	temsirolimus FDA Link 08/2020
1	Histones (Histone)IBA 01/2020
1	tazemetostatIBA 01/2020

Therapy/Procedure

38	Therapeutics 10/2022 - 03/2002
23	Stem Cell Transplantation 01/2022 - 03/2002
19	Drug Therapy (Chemotherapy) 01/2022 - 10/2007
9	Transplantation 01/2022 - 12/2009
4	Induction Chemotherapy 01/2022 - 01/2017
4	Radioimmunotherapy 01/2017 - 03/2008
3	Immunotherapy 10/2021 - 01/2018
3	Hematopoietic Stem Cell Transplantation 01/2020 - 06/2010
2	Combination Drug Therapy (Combination Chemotherapy) 01/2021 - 01/2018
2	Autologous Transplantation 01/2021 - 05/2019
2	BEAM regimen 01/2020 - 04/2011
2	Cell Transplantation 05/2019 - 02/2015
1	Injections 01/2022